ArticleCureus2026
Outcomes and Complications of Non-operative Management of Isolated Olecranon Fractures.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Non-operative management of olecranon fractures may be indicated in specific populations or when patients opt for conservative treatment after shared decision-making. In these instances, thorough understanding of operative and non-operative management outcomes can equip upper extremity surgeons with requisite knowledge to inform practice-specific fracture management pathways. We hypothesized that non-operative management of unilateral, isolated olecranon fractures results in satisfactory patient outcomes in terms of function, range of motion, and pain. Methods After International Review Board (IRB) approval, retrospective chart review was conducted on adults (>18 years) with unilateral, isolated olecranon fractures at a single multispecialty orthopedic practice from 2010 to 2024. Exclusion criteria included polytrauma and open injuries. Demographics, injury characteristics, fracture care management, complications, and functional outcomes were collected. Descriptive statistics were performed using SPSS version 28 (IBM, Armonk, NY). Results In 163 patients (mean age 73.2 ± 20.4), non-displaced (n = 57) and displaced (n = 106) fractures had similar range of motion (ROM): flexion 132° vs. 130° (p = 0.099), extension 11.1° vs. 11.3° (p = 0.523), supination 78.5° vs. 77.8° (p = 0.132); pronation was slightly higher in non-displaced (79.5° vs. 77.8°, p = 0.048). Complications were comparable (12.0% vs. 11.6%, p = 1.000); conversion to surgery was rare (1.79% vs. 0.94%, p = 1.000). Age-stratified analysis (<50, 50-59, 60-69, 70-79, 80-89, 90+) showed declining ROM with age: elbow flexion from 135° (<50) to 100° (90+) and extension from 6.05° (<50) to 15.9° (90+). Conclusion Non-operatively managed unilateral, isolated olecranon fractures demonstrated near-full elbow ROM at final follow-up visit. On average, ROM was comparable between displaced and non-displaced fractures, with no significant differences in flexion, extension, or supination; pronation was slightly reduced in displaced fractures (77.8° vs. 79.5°, p = 0.048). Overall complication rate was low (11.7%), and conversion to surgery was rare (1.23%), with no significant differences between displaced and non-displaced groups. Age-stratified analysis revealed statistically significant declining ROM and increasing complication and surgical conversion rates with increased age. This study reports the largest cohort of adult patients treated non-operatively for unilateral, isolated olecranon fractures, with age-stratified outcome data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.